member
coronaviru
famili
caus
global
public
health
emerg
base
analysi
hepat
c
viru
coronaviru
replic
molecular
structur
activ
viral
inhibitor
previous
reason
fdaapprov
heptat
c
drug
epclusa
sofosbuvirvelpatasvir
inhibit
coronavirus
includ
use
model
polymeras
extens
experi
demonstr
activ
triphosph
form
sofosbuvir
incorpor
lowfidel
polymeras
sarscov
rnadepend
rna
polymeras
rdrp
block
incorpor
polymeras
activ
triphosph
form
sofosbuvir
incorpor
hostlik
highfidel
dna
polymeras
use
molecular
insight
select
two
antivir
agent
alovudin
azt
fda
approv
hivaid
drug
evalu
inhibitor
sarscov
rdrp
demonstr
abil
two
hiv
revers
transcriptas
inhibitor
triphosph
triphosph
activ
triphosph
form
alovudin
azt
incorpor
sarscov
rdrp
also
termin
polymeras
extens
given
amino
acid
similar
sarscov
rdrp
expect
nucleotid
analogu
would
also
inhibit
polymeras
result
offer
guidanc
modifi
nucleotid
analogu
gener
potent
broadspectrum
anticoronaviru
agent
recent
appear
new
coronavir
infect
wuhan
china
worldwid
spread
made
intern
headlin
alreadi
death
ascrib
viru
reach
near
pandem
statu
viru
isol
lower
respiratori
tract
patient
pneumonia
sequenc
visual
electron
microscopi
viru
design
new
member
subgenu
sarbecoviru
orthocoronavirina
subfamili
distinct
merscov
sarscov
coronavirus
singl
strand
rna
virus
share
properti
singlestrand
rna
virus
hepat
c
viru
hcv
west
nile
viru
marburg
viru
hiv
viru
ebola
viru
dengu
viru
rhinovirus
particular
coronavirus
hcv
positivesens
singlestrand
rna
virus
thu
similar
replic
mechan
requir
rnadepend
rna
polymeras
rdrp
coronaviru
life
cycl
describ
briefli
viru
enter
cell
endocytosi
uncoat
posit
strand
rna
translat
produc
nonstructur
protein
precursor
includ
cystein
proteas
serin
proteas
cleav
precursor
form
matur
function
helicas
rnadepend
rna
polymeras
replicationtranscript
complex
ccbyncnd
biorxiv
preprint
sequenc
primer
templat
use
extens
reaction
shown
top
figur
polymeras
extens
reaction
perform
incub
utp
preassembl
sarscov
polymeras
indic
rna
templat
primer
appropri
reaction
buffer
follow
detect
reaction
product
malditof
ms
detail
procedur
shown
method
accuraci
mz
determin
da
form
respons
make
copi
rna
genom
via
negativesens
rna
intermedi
well
structur
protein
encod
viral
genom
viral
rna
packag
viral
coat
endoplasm
reticulumgolgi
intermedi
complex
exocytosi
result
releas
viral
particl
subsequ
infecti
cycl
potenti
inhibitor
design
target
nearli
everi
stage
process
howev
despit
decad
research
effect
drug
current
approv
treat
seriou
coronaviru
infect
sar
mer
one
import
druggabl
target
coronavirus
rnadepend
rna
polymeras
rdrp
polymeras
highli
conserv
protein
level
among
differ
posit
sens
rna
virus
coronavirus
hcv
belong
share
common
structur
featur
virus
like
rdrp
virus
coronaviru
enzym
highli
errorpron
might
increas
abil
accept
modifi
nucleotid
analogu
nucleotid
nucleosid
analogu
inhibit
polymeras
import
group
antivir
agent
base
analysi
hepat
c
viru
coronaviru
replic
molecular
structur
activ
viral
inhibitor
previous
reason
fdaapprov
heptat
c
drug
epclusa
sofosbuvirvelpatasvir
inhibit
coronavirus
includ
sofosbuvir
pyrimidin
nucleotid
analogu
prodrug
hydrophob
mask
phosphat
group
enabl
enter
infect
eukaryot
cell
convert
activ
triphosph
form
cellular
enzym
fig
activ
form
inhibit
hcv
rnadepend
rna
polymeras
activ
drug
meutp
bind
activ
site
rdrp
incorpor
rna
due
fluoro
methyl
modif
posit
inhibit
rna
chain
extens
therebi
halt
rna
replic
stop
viral
growth
act
rna
polymeras
inhibitor
compet
natur
ribonucleotid
velpatasvir
inhibit
key
protein
requir
hcv
replic
enhanc
function
rna
polymeras
viral
rna
synthesi
fig
convers
sofosbuvir
activ
triphosph
meutp
vivo
inhibit
viral
polymeras
adapt
mani
rna
polymeras
inhibitor
evalu
antivir
drug
relat
purin
nucleotid
prodrug
remdesivir
fig
develop
gilead
treat
ebola
viru
infect
though
success
current
clinic
trial
treat
contrast
sofosbuvir
fig
group
remdesivir
fig
unmodifi
cyano
group
posit
serv
inhibit
rdrp
activ
triphosph
form
addit
use
hydrophob
group
mask
phosphat
protidebas
prodrug
strategi
sofosbuvir
remdesivir
class
nucleosid
prodrug
includ
base
ester
deriv
ribos
hydroxyl
group
enhanc
cellular
deliveri
replic
cycl
hcv
similar
coronavirus
analyz
structur
activ
triphosph
form
sofosbuvir
fig
compar
remdesivir
fig
alreadi
shown
inhibit
replic
specif
rna
virus
sofosbuvir
hcv
remdesivir
note
particular
sofosbuvir
fluoro
methyl
group
substanti
smaller
group
group
remdesivir
bulki
cyano
group
close
proxim
may
lead
steric
hindranc
impact
incorpor
effici
activ
form
remdesivir
interestingli
recent
report
use
merscov
polymeras
triphosph
remdesivir
preferenti
incorpor
rel
atp
solut
assay
nevertheless
shown
activ
triphosph
form
remdesivir
caus
complet
polymeras
reaction
termin
actual
delay
polymeras
termin
ebola
viru
respiratori
syncyti
viru
like
due
group
free
group
compar
activ
form
sofosbuvir
two
nucleotid
inhibitor
relat
structur
review
incorpor
polymeras
rna
synthesi
may
continu
past
incorpor
nucleotid
analogu
shown
termin
reaction
catalyz
hcv
rdrp
proofread
mechan
revert
inhibit
mitochondri
dnadepend
rna
polymeras
addit
hcv
develop
resist
due
mutat
rdrp
comput
studi
publish
consid
abil
variou
antihcv
drug
dock
activ
site
sar
mer
coronaviru
rdrp
potenti
inhibitor
recent
elfiki
use
comput
approach
predict
sofosbuvir
ribavirin
remidisvir
might
potent
drug
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
thu
base
analysi
biolog
pathway
hepat
c
coronavirus
molecular
structur
activ
viral
inhibitor
model
polymeras
sarscov
rdrp
extens
experi
describ
efficaci
sofosbuvir
inhibit
hcv
rdrp
expect
sofosbuvir
modifi
form
also
inhibit
polymeras
activ
triphosph
form
sofosbuvir
meutp
shown
incorpor
hcv
rdrp
prevent
incorpor
polymeras
viral
polymeras
also
shown
incorpor
activ
form
variou
antivir
prodrug
inhibit
replic
sinc
time
prepar
manuscript
access
rdrp
first
select
two
group
polymeras
test
termin
effici
activ
form
sofosbuvir
one
group
high
fidel
behavior
regard
incorpor
modifi
nucleotid
analogu
one
would
expect
host
cell
polymeras
group
low
fidel
mimick
viral
polymeras
well
rdrp
sarscov
viru
caus
subsequ
outbreak
sar
rational
low
fidel
virallik
enzym
would
incorpor
meutp
stop
replic
high
fidel
polymeras
typic
host
cell
polymeras
would
experiment
proof
termin
sarscov
polymeras
catalyz
rna
replic
would
provid
support
rational
indic
sofosbuvir
modifi
form
inhibit
first
carri
dna
polymeras
extens
reaction
activ
form
sofosbuvir
meutp
use
thermo
sequenas
exampl
high
fidel
hostlik
polymeras
two
mutat
dna
polymeras
known
promiscu
abil
incorpor
modifi
nucleotid
thermin
ii
thermin
ix
exampl
virallik
low
fidel
enzym
dna
templateprim
complex
next
two
avail
base
fig
incub
either
meutp
structur
shown
fig
dttp
posit
control
appropri
polymeras
buffer
meutp
incorpor
inhibit
incorpor
singlebas
primer
extens
product
produc
contrast
dttp
incorpor
result
primer
extens
base
perform
reaction
determin
molecular
weight
extens
product
use
malditofmass
spectrometri
malditof
ms
seen
fig
primertempl
complex
sequenc
shown
top
fig
meutp
incub
low
fidel
n
polymeras
mutant
thermin
ii
thermin
ix
observ
singl
product
peak
molecular
weight
da
da
indic
singl
base
extens
polymeras
reaction
thu
meutp
abl
incorpor
block
nucleotid
incorpor
contrast
extens
reaction
carri
highfidel
thermo
sequenas
dna
polymeras
ts
incorpor
evidenc
singl
primer
peak
da
fig
support
rational
thermo
sequenas
high
fidel
enzym
origin
design
accur
sanger
sequenc
incorpor
meutp
lowfidel
polymeras
incorpor
meutp
stop
nucleotid
incorpor
dttp
use
posit
control
three
enzym
incorpor
continu
past
first
templat
result
higher
molecular
weight
peak
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
sequenc
primer
templat
use
extens
reaction
shown
top
figur
polymeras
extens
reaction
perform
incub
primer
templat
meutp
appropri
reaction
buffer
specif
enzym
follow
detect
reaction
product
malditof
ms
ms
spectra
thermin
ii
thermin
ix
b
indic
singlebas
incorpor
termin
ms
spectrum
thermo
sequenas
ts
c
indic
incorpor
show
primer
peak
accuraci
mz
determin
da
result
demonstr
lower
fidel
polymeras
high
likelihood
incorpor
meutp
inhibit
viral
rna
replic
wherea
high
fidel
enzym
typic
host
dna
rna
polymeras
low
likelihood
inhibit
meutp
antivir
drug
design
base
principl
may
lead
potent
viral
polymeras
inhibitor
fewer
side
effect
provid
proof
rdrp
might
inhibit
meutp
next
test
abil
molecul
incorpor
rna
primer
termin
reaction
catalyz
rdrp
sarscov
use
rna
templat
shown
fig
activ
triphosph
form
drug
incorpor
rdrp
prevent
incorpor
behav
termin
polymeras
reaction
base
similar
insight
relat
molecular
structur
previou
antivir
activ
studi
comparison
sofosbuvir
select
triphosph
form
alovudin
azidothymidin
azt
first
fda
approv
drug
hivaid
evalu
inhibitor
sarscov
rdrp
two
molecul
share
similar
backbon
structur
base
ribos
sofosbuvir
fewer
modif
site
less
steric
hindranc
furthermor
modif
alovudin
azt
carbon
place
oh
group
directli
prevent
incorpor
nucleotid
lead
perman
termin
rna
synthesi
replic
viru
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
alovudin
one
potent
inhibitor
hiv
revers
transcriptas
replic
promis
drug
discontinu
phase
ii
trial
due
hematolog
toxic
howev
subsequ
vitro
studi
show
alovudin
effect
suppress
sever
nucleosidenucleotid
revers
transcriptas
inhibitor
nrti
resist
mutant
new
clinic
studi
carri
low
dose
alovudin
given
supplement
patient
show
evid
infect
nrti
resist
hiv
strain
respond
well
current
drug
regimen
cours
mgday
alovudin
reduc
viral
load
significantli
rel
well
toler
unexpect
advers
event
azt
anoth
antiretrovir
medic
long
use
prevent
treat
hivaid
upon
entri
infect
cell
similar
alovudin
cellular
enzym
convert
azt
effect
form
dttp
structur
shown
fig
compet
dttp
incorpor
dna
hivrevers
transcriptas
result
termin
hiv
dna
synthesi
sinc
side
effect
toxic
azt
well
understood
novel
methodolog
direct
enhanc
azt
plasma
level
bioavail
human
organ
order
improv
therapeut
efficaci
among
possibl
azt
prodrug
strategi
propos
thu
assess
abil
dttp
activ
triphosph
form
azt
alovudin
along
meutp
incorpor
sarscov
rdrp
rna
primer
termin
polymeras
reaction
rdrp
sarscov
refer
two
protein
cofactor
shown
requir
process
polymeras
activ
clone
purifi
describ
three
viral
gene
product
high
homolog
eg
ident
similar
similar
homolog
level
amino
acid
level
equival
gene
product
caus
agent
detail
descript
homolog
includ
extend
data
fig
highlight
key
function
motif
describ
kirchdoerf
ward
motif
b
e
f
g
ident
sarscov
amino
acid
level
motif
c
display
conserv
substitut
perform
polymeras
extens
assay
meutp
dttp
utp
follow
addit
preanneal
rna
templat
primer
preassembl
mixtur
rdrp
two
cofactor
protein
extend
primer
product
reaction
subject
malditofm
analysi
rna
templat
primer
correspond
epitop
region
n
protein
viru
use
polymeras
assay
sequenc
indic
top
fig
two
row
next
avail
posit
templat
rna
polymeras
extens
downstream
prime
site
meutp
dttp
incorpor
viral
rdrp
singl
nucleotid
analogu
ad
primer
strand
inde
inhibitor
polymeras
extens
stop
incorpor
prevent
case
utp
control
reaction
two
utp
incorpor
shown
fig
extend
data
fig
exactli
observ
malditof
ms
trace
fig
peak
summari
result
demonstr
nucleotid
analogu
meutp
dttp
perman
termin
sarscov
rdrp
prodrug
version
sofosbuvir
dt
nucleosid
dt
nucleosid
readili
synthes
use
protid
prodrug
approach
shown
fig
c
develop
therapeut
sar
sequenc
primer
templat
use
extens
reaction
within
code
sequenc
genom
shown
top
figur
polymeras
extens
reaction
perform
incub
meutp
b
c
dttp
preassembl
sarscov
polymeras
indic
rna
templat
primer
appropri
reaction
buffer
follow
detect
reaction
product
malditof
ms
detail
procedur
shown
method
section
comparison
data
extens
utp
present
extend
data
fig
accuraci
mz
determin
da
one
factor
confound
develop
rdrp
inhibitor
coronavirus
presenc
proofread
activ
associ
key
compon
replicationtranscript
complex
sarscov
also
encod
exonucleas
activ
overcom
use
nucleotid
importantli
sinc
sofosbuvir
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
azt
fda
approv
drug
toxic
test
alreadi
perform
evalu
quickli
laboratori
clinic
set
recent
describ
strategi
design
synthes
viral
polymeras
inhibitor
combin
protid
prodrug
approach
use
develop
sofosbuvir
use
group
previous
built
nucleotid
analogu
function
termin
dna
sequenc
synthesi
reason
hydrophob
phosphat
mask
group
allow
entri
compound
virusinfect
cell
ii
group
either
free
modif
posit
encourag
incorpor
activ
triphosph
analogu
viral
polymeras
host
cell
polymeras
thu
reduc
side
effect
iii
incorpor
extens
prevent
virtu
group
therebi
complet
inhibit
viral
replic
potenti
overcom
develop
resist
due
accumul
new
mutat
rdrp
design
criterion
identifi
group
attach
appropri
structur
chemic
properti
eg
size
shape
rigid
flexibl
polar
reactiv
eg
stabil
cellular
enzym
along
appropri
incorpor
viral
rdrp
minim
incorpor
host
polymeras
previous
use
chemic
structur
principl
select
varieti
chemic
moieti
block
nucleotid
analogu
polymeras
termin
conclus
demonstr
capabl
toler
dna
polymeras
well
sar
cov
rnadepend
rna
polymeras
nearli
ident
rdrp
respons
incorpor
meutp
activ
form
sofosbuvir
serv
termin
polymeras
reaction
also
show
two
nucleotid
triphosph
activ
form
alovudin
dttp
activ
form
azt
also
incorpor
termin
nucleotid
extens
rdrp
polymeras
reaction
potenti
prevent
replic
viru
prodrug
version
compound
deriv
therefor
develop
potent
broadspectrum
therapeut
coronaviru
infecti
diseas
includ
sar
mer
also
less
conserv
coronavirus
within
next
region
interfac
domain
aa
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
first
amino
acid
posit
multipl
substitut
rest
interfac
domain
quit
conserv
region
beyond
interfac
domain
correspond
cterminu
contain
polymeras
function
domain
domain
constitut
canon
finger
palm
thumb
polymeras
enzym
contain
sever
motif
conserv
among
coronavirus
motif
f
amino
acid
substitut
sarscov
three
substitut
locat
within
motif
three
similar
amino
acid
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
